The increasing use of biologic agents for chronic treatment of Crohn’s disease and ulcerative colitis has meant that corticosteroids are typically reserved for use during flares. The intermittent use of these efficacious therapies has uncovered a new issue—secondary adrenal insufficiency when corticosteroids are withdrawn.